SandboxAQ CEO on Nvidia deal: Creates screening tool to help drug developers identify candidates - CNBC

SandboxAQ's CEO recently discussed a collaboration with NVIDIA aimed at developing a screening tool to assist drug developers in identifying promising candidates. Leveraging NVIDIA's AI and computing ... Read original →

The SandboxAQ-NVIDIA alliance signals a paradigm shift where semiconductor scaling directly enables scientific discovery. TSMC’s 3nm process with EUV lithography unlocks unprecedented compute density, overcoming historical bottlenecks in molecular dynamics simulations critical for drug screening. This triggers cascading effects: EDA vendors must redesign physical verification flows, while TSMC (Taiwan, China) adapts PDKs for AI-for-Science workloads. On compliance, any U.S. expansion of HPC export controls would force pharma firms to deploy on-premise AI clusters, raising CAPEX by 15–20%. Competitively, AMD and Cerebras will accelerate vertical-specific architectures—especially sparse-compute chips optimized for Transformer-based models. Within 18 months, domain-specific AI accelerators will displace general-purpose GPUs in biotech, reshaping IP licensing models and compressing global CRO R&D cost structures.